Dr. Peter Levison, Senior Marketing Director – Downstream Processing, Pall Biotech talks about the evolution and benefits of continuous biomanufacturing, what implementation looks like today and what still needs to be realized for full industry adoption.

Continuous Biomanufacturing Implementation Now and in The Future

The Downstream Column (DsC) is an online publication targeting members of the biologics industry. Our intent is to provide a community to share expertise and best practices as well as discuss topics of interest. The Downstream Column covers areas important to the research, discovery, development, and manufacture of biologic therapeutics. Key industry coverage areas include: purification, formulation, fill/finish and QA/QC for cell and gene therapies, vaccines, biologics, and emerging therapeutic modalities.

Share Continuous Biomanufacturing Implementation Now and in The Future

Sign up to save your podcasts

Continuous Biomanufacturing Implementation Now and in The Future

Continuous Biomanufacturing Implementation Now and in The Future